Compare IQV & CQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IQV | CQP |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 29.3B |
| IPO Year | 2013 | 2006 |
| Metric | IQV | CQP |
|---|---|---|
| Price | $207.07 | $61.82 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 16 | 7 |
| Target Price | ★ $227.13 | $60.43 |
| AVG Volume (30 Days) | ★ 1.5M | 165.2K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 5.05% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 1.61 | 0.07 |
| Revenue | $9,739,000,000.00 | ★ $10,758,000,000.00 |
| Revenue This Year | $6.77 | $6.35 |
| Revenue Next Year | $5.89 | $1.27 |
| P/E Ratio | ★ $128.19 | $880.71 |
| Revenue Growth | ★ 41.60 | 23.60 |
| 52 Week Low | $154.50 | $49.53 |
| 52 Week High | $247.05 | $70.64 |
| Indicator | IQV | CQP |
|---|---|---|
| Relative Strength Index (RSI) | 73.43 | 49.65 |
| Support Level | $159.91 | $57.38 |
| Resistance Level | $209.48 | $67.08 |
| Average True Range (ATR) | 6.76 | 2.28 |
| MACD | 2.83 | 0.12 |
| Stochastic Oscillator | 97.29 | 58.05 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.